Quality of treatment and surgical approach for rectal gastrointestinal stromal tumour (GIST) in a large European cohort
Nikki S. IJzerman(Erasmus MC), Myles Smith(Royal Marsden NHS Foundation Trust), Ioannis Zavrakidis(The Netherlands Cancer Institute), Marco Fiore(Fondazione IRCCS Istituto Nazionale dei Tumori), Hans Gelderblom(Leiden University Medical Center), Neeltje Steeghs(Peter MacCallum Cancer Centre), Elena Fumagalli(Fondazione IRCCS Istituto Nazionale dei Tumori), Sylvie Bonvalot(Dana-Farber Cancer Institute), Jos A. van der Hage(Leiden University Medical Center), Charles Honoré(Institut Gustave Roussy), Mahmoud Mohammadi(Leiden University Medical Center), Elżbieta Bylina(The Maria Sklodowska-Curie National Research Institute of Oncology), Winan J. van Houdt(Diakonessenhuis hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Paris Tekkis(Imperial College London), Dirk J. Grünhagen(Erasmus MC), Han J. Bonenkamp(Radboud University Nijmegen), Boudewijn van Etten(University Medical Center Groningen), Dimitri Tzanis(Université Paris Cité), Shahnawaz Rasheed(Royal Marsden Hospital), Yvonne Schrage(The Netherlands Cancer Institute)
Cited by 42
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k